Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2023-04-18 11:15:05
Oslo, Norway,18 April 2023
Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company")
announces that full results from its Phase 2 clinical trials of Betalutin®
(177Lu lilotomab satetraxetan) in resistant/refractory (R/R) indolent non
-Hodgkin's lymphoma (NHL) have been published at EudraCT, the European Union
Drug Regulating Authorities Clinical Trials Database (the database for all
interventional clinical trials on medicinal products submitted to the National
Competent Authorities (NCAs) of the European Union). The data from the Phase
1b/2a LYMRIT 37-01 and the Phase 2b PARADIGME studies can be found via this
link:
EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/ctr
-search/trial/2011-000033-36/results)
As previously announced on 5 July 2022, the PARADIGME trial of Betalutin® in 3rd
-line follicular lymphoma patients refractory to rituximab/anti-CD20 (3L R/R FL)
was discontinued following a comprehensive review and independent data
evaluation and a subsequent request for regulatory agency interaction. The data
from the 109 patients enrolled in PARADIGME up until its discontinuation show:
· Overall response rate (ORR) was 38.9% and 32.1%